1405 todd manning

9
ABBVIE: A NEW PLAYER IN ONCOLOGY Todd Manning General Manager, AbbVie Ltd

Transcript of 1405 todd manning

ABBVIE: A NEW PLAYER IN ONCOLOGYTodd ManningGeneral Manager, AbbVie Ltd

“The AbbVie oncology products are all investigational in nature and are currently not licensed in any country. The ultimate licensing of these compounds is subject to regulatory review and approval.”

2

AbbVie Oncology Vision

We will accomplish this by:• Leveraging our leading-edge platforms• Working closely with academia, diagnostic companies and cooperative

groups• Bringing to market novel therapeutics with transformational increases in

efficacy and safety

Transform the Lives of People with Cancer

It starts with science……and continues with AbbVie’s commitment to research and development

3

Oncology is a new focus for AbbVie

AbbVie has a rich oncology pipeline in more than 15 different tumour types

AbbVie’s late phase pipeline includes treatments for both haematological malignancies and solid tumours

4

Phase 17 molecules

Phase 21 molecule

Phase 33 molecules

PARP inhibitor(solid tumours)

potential indications6

Phase 2/3 trials19

BCL-2 inhibitor(haem malignancies)

potential indications6

Phase 2/3 trials7

EGFR ADC(glioblastoma)

potential indications2

Phase 2/3 trials2

PI3K inhibitor(haem malignancies)

potential indications6

Phase 2/3 trials10

5

Global Trials in Solid Tumours

Brain Metastases Breast NSCLC SCLC Colorectal Ovarian Gastric Glioblastoma

In 2014 - • ~1100 subjects enrolled in Phase 1-3 trials• ~60 trials performed across multiple tumours• Studies conducted in 44 countries

AbbVie’s oncology clinical development is founded on deep scientific and clinical expertise

Global Trials in Haem. Malignancies

Acute Myelogenous Leukemia Chronic Lymphocytic Leukemia Multiple Myeloma Non-Hodgkin’s Lymphoma

Current Trials in Ireland

Squamous non-small cell lung cancer Glioblastoma

Manufacturing in Ireland: 2 of AbbVie’s 3 oncology compounds in phase 3 trials are manufactured in Ireland

• Each of the uniquely focused sites in Ireland manufactures portions of AbbVie’s top 20 products

• The company has 12 sites in total across the United States, Europe and Puerto Rico, as well as strategic partnerships with third-party manufacturers

• Of the 3 oncology compounds in phase 3 trials, 2 are manufactured in Ireland

6

In addition to organic development of new compounds, AbbVie is also investing heavily in the oncology pipeline

7

Summary

• AbbVie is new to oncology, and has a number of compounds in pre-clinical, early phase and late phase development

• Late phase trials include both solid tumours and haematological malignancies, and enrolled over 1100 patients in 2014

• AbbVie is investing in acquisitions and licensing compounds, in addition to the discovery and development process

8